In Vivo CAR-T Development Service with IVT CircRNA Technology

The Potential of In Vivo Circular RNA-based CAR-T Engineering

As a potential tumor immunotherapy method, in vivo CAR therapy takes advantage of multiple advantages to solve the current traditional methods of preparing CAR-T ex vivo, such as more economical, more convenient production, and less toxicity. Non-viral lipid nanoparticles represent an important approach being explored for in vivo engineering. Circular RNA-based in vivo CAR-T engineering as a novel solution for tumor immunotherapy.

Fig.1 The crosstalk among circRNA, miRNA, and mRNA in hematological malignancies.¹

Our In Vivo Circular RNA-based CAR-T Cell Engineering Service

To boost the development of CAR-T therapy, Creative Biolabs has successfully established a cost-effective in vivo circular RNA-based CAR-T engineering service to satisfy the diverse demands of our global customers. Our in vivo circular RNA-based CAR-T engineering service combines novel technology to design circular RNA transcripts that drive protein expression with validated and unique LNP delivery solutions. We provide customized optimized circular RNA-LNPs which offer simplified production, improved stability, and superior yield to empower in vivo CAR-T engineering.

Fig.2 The mechanism of circRNAs in immunotherapy.²

What Will You Gain

Our Development Process

Required Starting Materials:

• Target antigen and CAR construct sequences or design specifications.
• Relevant cell type or animal model information for preclinical studies.
• Desired expression duration, dosing strategies, or therapeutic endpoints.

Workflow of In Vivo Circular RNA-based CAR-T Cell Engineering. (Creative Biolabs Original)

The final deliverables include a detailed experimental design report with circRNA sequence and LNP formulation, in vivo expression and functional validation data, and a comprehensive project summary with development recommendations.

Work With Creative Biolabs

In the field of in vivo CAR-T engineering, we are committed to developing new approaches to greatly enhance its effectiveness in cancer therapy. At the same time, we also provide the following related services:

• In Vivo IVT mRNA-based CAR-T Cell Engineering Service
• In Vivo Viral-based CAR-T Cell Engineering Service

Benefits for Your Program

• Comprehensive in vivo CAR-T cell engineering, from design and optimization of CAR constructs to functional validation in preclinical models.
• Advanced IVT circRNA and LNP delivery platforms for efficient and safe in vivo CAR expression.
• Customizable CAR design, including target specificity, co-stimulatory domains, and optimized expression kinetics.
• Scalable service workflow, supporting multiple therapeutic targets and research models.
• Stringent quality control system, including analytical validation, functional assessment, and regulatory-compliant documentation.

Frequently Asked Questions

How to Contact Us

Creative Biolabs' In Vivo CAR-T Development with IVT CircRNA Technology offers a next-generation platform to engineer functional CAR-T cells in vivo efficiently and safely. With expertise in circRNA design, LNP delivery, and preclinical validation, clients can accelerate therapeutic development, reduce costs, and enhance CAR-T performance. Reach out for detailed information and to discuss your project: Contact Our Team for More Information and to Discuss Your Project. Our experts are ready to provide tailored solutions and guidance for your in vivo CAR-T development needs.

References

1. Zhou, Xiangxiang, et al. "The functions and clinical significance of circRNAs in hematological malignancies." Journal of hematology & oncology 13.1 (2020): 138.
2. Fang, Zhixiao, Chunjie Jiang, and Shengli Li. "The potential regulatory roles of circular RNAs in tumor immunology and immunotherapy." Frontiers in Immunology 11 (2021): 617583.